A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Rosmantuzumab (Primary)
- Indications Colorectal cancer; Gastric cancer; Solid tumours
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 09 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Apr 2018.
- 04 Jan 2018 According to an OncoMed Pharmaceuticals media release, data from the trial ill be presented at a future medical conference.
- 04 Jan 2018 Status changed from recruiting to active, no longer recruiting, as reported in an OncoMed Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History